IMVT (Immunovant) Operating Cash Flow per Share : $-2.47 (TTM As of Mar. 2025)

View and export this data going back to 2019. Start your Free Trial

What is Immunovant Operating Cash Flow per Share?

Immunovant's operating cash flow per share for the three months ended in Mar. 2025 was $-0.66. Immunovant's operating cash flow per share for the trailing twelve months (TTM) ended in Mar. 2025 was $-2.47.

During the past 3 years, the average Operating Cash Flow per Share Growth Rate was -36.90% per year. During the past 5 years, the average Operating Cash Flow per Share Growth Rate was -16.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.

The historical rank and industry rank for Immunovant's Operating Cash Flow per Share or its related term are showing as below:

IMVT' s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: -36.9 Med: -17.8 Max: -7.4
Current: -36.9

During the past 7 years, Immunovant's highest 3-Year average Operating Cash Flow per Share Growth Rate was -7.40% per year. The lowest was -36.90% per year. And the median was -17.80% per year.

IMVT's 3-Year OCF Growth Rate is ranked worse than
89.25% of 1219 companies
in the Biotechnology industry
Industry Median: 9.2 vs IMVT: -36.90

Immunovant Operating Cash Flow per Share Historical Data

The historical data trend for Immunovant's Operating Cash Flow per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immunovant Operating Cash Flow per Share Chart

Immunovant Annual Data

Trend

Dec18

Mar20

Mar21

Mar22

Mar23

Mar24

Mar25

Operating Cash Flow per Share

Get a 7-Day Free Trial

-0.95

-0.97

-1.53

-1.55

-2.48

Immunovant Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Operating Cash Flow per Share	Get a 7-Day Free Trial															-0.41	-0.52	-0.61	-0.68	-0.66

Competitive Comparison of Immunovant's Operating Cash Flow per Share

For the Biotechnology subindustry, Immunovant's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Immunovant's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Immunovant's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Immunovant's Price-to-Operating-Cash-Flow falls into.

Save Embed

;

Save Embed

;

Immunovant Operating Cash Flow per Share Calculation

Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.

Immunovant's Operating Cash Flow per Share for the fiscal year that ended in Mar. 2025 is calculated as

Operating Cash Flow per Share (A: Mar. 2025 )	=	Cash Flow from Operations (A: Mar. 2025 )	/	Shares Outstanding (Diluted Average) (A: Mar. 2025 )
	=	-375.874	/	151.574
	=	-2.48

Immunovant's Operating Cash Flow per Share for the quarter that ended in Mar. 2025 is calculated as

Operating Cash Flow per Share (Q: Mar. 2025 )	=	Cash Flow from Operations (Q: Mar. 2025 )	/	Shares Outstanding (Diluted Average) (Q: Mar. 2025 )
	=	-110.637	/	166.613
	=	-0.66

Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.47

Immunovant Operating Cash Flow per Share Related Terms

Thank you for viewing the detailed overview of Immunovant's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Immunovant Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immunovant Inc (NAS:IMVT) » Definitions » Operating Cash Flow per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

320 West 37th Street, 6th Floor, New York, NY, USA, 10018

Website

https://www.immunovant.com

Immunovant Inc is a clinical-stage biopharmaceutical company. It is focused on enabling normal lives for patients with autoimmune diseases. The company's product includes batoclimab and IMVT-1402 targets the neonatal Fc receptor (FcRn).

Executives

Jay S Stout	officer: Chief Technology Officer	C/O VERSARTIS, INC., 4200 BOHANNON DR., SUITE 250, MENLO PARK CA 94025
Eva Renee Barnett	officer: Chief Financial Officer	C/O IMMUNOVANT, INC., 320 WEST 37TH STREET, 6TH FLOOR, NEW YORK NY 10018
Peter Salzmann	director, officer: Chief Executive Officer	320 W 37TH STREET, 3RD FLOOR, NEW YORK NY 10016
Andrew J. Fromkin	director	C/O RADIUS HEALTH, INC., 201 BROADWAY, 6TH FL, CAMBRIDGE MA 02139
William L. Macias	officer: Chief Medical Officer	C/O IMMUNOVANT, INC., 320 WEST 37TH STREET, 6TH FLOOR, NEW YORK NY 10018
Roivant Sciences Ltd.	10 percent owner	CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11
Atul Pande	director	C/O AXOVANT SCIENCES, INC., 1441 BROADWAY, 3RD FLOOR, NEW YORK NY 10018
Douglas J. Hughes	director	C/O EARGO, INC., 2665 NORTH FIRST STREET, SUITE 300, SAN JOSE CA 95134
Mark S. Levine	officer: Chief Legal Officer	1601 TRAPELO ROAD, SUITE 284, WALTHAM MA 02451
Julia G. Butchko	officer: Chief Dev. & Tech. Officer	320 W 37TH STREET, 3RD FLOOR, NEW YORK NY 10016
George V Migausky	director	C/O DYAX CORP., 300 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Frank Torti	director	2855 SAND HILL ROAD, MENLO PARK CA 94025
Rita Jain	officer: Chief Medical Officer	C/O AKEBIA THERAPEUTICS, INC., 245 FIRST STREET, SUITE 1100, CAMBRIDGE MA 02142
Michael James Elliott	officer: Chief Scientific Officer	320 WEST 37TH STREET, NEW YORK NY 10018
Eric Venker	director	C/O ROIVANT SCIENCES, INC., 320 WEST 37TH STREET, 6TH FLOOR, NEW YORK NY 10018